Abstract
Direct oral anticoagulants (DOACs; apixaban, dabigatran, edoxaban, and rivaroxaban),) are used in the management of patients with atrial fibrillation, ischemic heart disease, venous thromboembolism, and valvular heart disease. These drugs also increase the risk of gastrointestinal (GI) bleeding from luminal sources such as ulcers or diverticula and after endoscopic procedures.1-2 Rivaroxaban is a direct competitive inhibitor of factor Xa and limits thrombin generation in a dose dependent manner.6 Although no serious bleeding was reported in the endoscopic mucosal biopsy performed under rivaroxaban in the literature. in our case, hemorrhagic shock developed due to leakage in the biopsy area as a result of antrum biopsy performed under rivaroxaban.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Medical Science and Clinical Invention
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
